Overview

Effect of Cardiotoxic Anticancer Chemotherapy on the Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria

Status:
Enrolling by invitation

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

The anthracycline doxorubicin, first introduced in the 1960's, continues to be an effectively utilized antineoplastic drug. Even at relatively low cumulative doses there is risk of cardiotoxicity. However, the incidence of subclinical cardiotoxicity is not known, carrying a potential risk for late effects in cancer survivors. Doxorubicin has systemic toxicity that may contribute to cardiac metabolic stress, but the main cardiotoxic mechanism involves cardiac mitochondria. The goal of this study is to detect early changes in the mitochondrial metabolism in situ as a marker for subclinical doxorubicin induced cardiotoxicity.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Texas Southwestern Medical Center

Treatments:

Doxorubicin
Liposomal doxorubicin